1-6 of 6
Ida H Hiemstra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Andrew Spencer, Katrine Fladeland Iversen, Binod Dhakal, Maria Creignou, Jenny Chen, Ida H Hiemstra, Sieto Bosgra, Avani Badani, Esther C.W. Breij, Lauren K. Brady, A. Kate Sasser, Anders Malmberg, Henrik Gregersen, Markus Hansson, Annemiek Broijl, Maria-Victoria Mateos, Torben Plesner
Journal: Blood
Blood (2022) 140 (Supplement 1): 7320–7321.
https://doi.org/10.1182/blood-2022-159116
Published: 2022
Journal Articles

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra, PhD, Maarten L Janmaat, PhD, Peter Boross, PhD, Jeroen van den Brakel, Wessel ten Hagen, Sanne van Dooremalen, Sieto Bosgra, PhD, Bart ECG De Goeij, PhD, Grietje Andringa, Laurens Kil, PhD, A Kate Sasser, PhD, Tahamtan Ahmadi, MD PhD, David Satijn, PhD, Esther CW Breij, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-140313
Published: 2020
Journal Articles

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Tommy Li, PhD, Ida H Hiemstra, PhD, Christopher Chiu, PhD, Roberto S Oliveri, MD PhD, Dena DeMarco, Theodora W. Salcedo, PhD DABT, Frederikke Lihme Egerod, PhD, Manish Gupta, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-139457
Published: 2020
Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 758.
https://doi.org/10.1182/blood-2019-121460
Published: 2019
Journal Articles

Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo , Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

Hilma J Van Der Horst, MSc, A. Vera de Jonge, Ida H Hiemstra, PhD, Anne T Gelderloos, MSc, Daniella RAI Berry, Nathalie J Hijmering, Daphne de Jong, Prof Dr, Martine E.D. Chamuleau, Sonja Zweegman, MD PhD, Esther CW Breij, DPhil, Margaretha GM Roemer, PhD, Tuna Mutis
Journal: Blood
Blood (2019) 134 (Supplement_1): 4066.
https://doi.org/10.1182/blood-2019-125765
Published: 2019
Journal Articles

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Ida H. Hiemstra, PhD, Patrick J. Engelberts, BS, Bart de Jong, BS, Danita H Schuurhuis, PhD, Theodora W. Salcedo, PhD DABT, Sandra Verploegen, PhD, Marten van der Zee, PhD, Arnout F. Gerritsen, PhD, Nedjad Losic, PhD, Sjeng Horbach, PhD, Roberto Oliveri, MD PhD, Jeroen J. Lammerts van Bueren, PhD, Pernille Autzen Usher, PhD, Janine Schuurman, PhD, Paul W. H. I. Parren, PhD, Esther C. W. Breij, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1664.
https://doi.org/10.1182/blood-2018-99-115957
Published: 2018